Innovative Medical Payment Services

Established in 2017 in Shanghai, MediTrust connects insurance groups, pharmaceutical stores and
patients on one platform. The specialist manages to offer a clutch of payment services when it comes
to chronic diseases, rare diseases, and medical equipment.

1. Business model (Internet + Hospital + Medicine + Insurance)

MediTrust has innovative medical payment services in its core to enable multiple stakeholders in health
insurance value chain, including pharmaceutical companies, DTP (direct to patient) pharmacies, health insurance
companies and hospitals.
• Demand side: aggregating patients’ need of medicines for chronic and rare diseases, and medical
equipments
• Supply side: pharmaceutical companies, DTP pharmacies, insurance companies and hospitals

4 Major business lines

• Yao Kang Fu: Innovative medical payment and medical ecommerce (2C with its own app)
- Demand side: addressing various patients’ pain points, such as inaccessibility to certain medicines,
affordability and therapeutic inefficacy issues. MediTrust has over 30 innovations in this area,
including installment payment solutions for expensive medicines, insurance for therapeutic efficacy,
payment discounts and others
- Supply side: precise marketing for pharmaceutical companies to reach their customers and more
effective sales conversion

• Innovative Health Insurance

- Over 50 insurance products on medicines, starting with special medicines for tumors
- Other innovative products on medical equipments and innovative therapies

• Citywide complementary medical insurance (currently available in Hangzhou, Suzhou, etc.)

- Improve the availability and accessabiliy of medicines for local citizens, and address the financial
strains caused by high medical expenditures
- Shanghai Pharmaceuticals and China Life Re-insurance as its shareholders and important strategic
partners to ensure the supply of medicines and its risk management capabilities

• Internet hospital (MediTrust Internet Hospital in Hainan Province)

- Providing new medicines, therapies and medical equipments to patients
- Promoting the development of medical services infrastructure

2. Key metrics
Yao Kang Fu
• Pharmaceutical partners :50+
• The most extensive coverage of expensive drugs for cancers and chronic diseases
• Covering most of DTP (direct to patient) pharmacies in over 400 cities in China
• Has benefited over 1 million patients on saving over 1 billion RMB medical expenditures

Citywide complementary medical insurance

• Covering the largest number of cities among its competitors
• No.1 in the number of total policies issued

3. Fundraising history
• March 2020, strategic investment by China Life Re-insurance
• March 2021, Series B of 1 billion RMB by shareholders in medical services, health insurance and internet
industries
- Lead investors: Ant Financials, Shanghai Biomedical Fund, Sinovation Ventures
- Other investors: Huaxin Growth Fund, Northern Light Venture Capital
- Existing investors: Boyuan Capital, Yuan Yi Capital, SAIF Partners
4. Strategic partners
• AstraZeneca
• ZaiLab
• Pfizer
• Lilly
• Wesure
• PingAn
• AIA
• TaiKang